AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18502229 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia food safety education program on a computer kiosk
Number of subjects: 394
Study 18502229 — intervention group
Group type: COMPARATOR
Intervention: Food safety pamphlets
Number of subjects: 394
Study 16553340 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-locking device technique (group N)
Number of subjects: 230
Study 16553340 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (group C)
Number of subjects: 230
Study 12882671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with 50 mg mitomycin bound to 375 mg carbon adsorbent (MMC‐CH)
Number of subjects: 124
Study 12882671 — intervention group
Group type: COMPARATOR
Intervention: Control group (systemic chemotherapy 3 months after operation)
Number of subjects: 124
Study 11746535 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume leukapheresis (LVL)
Number of subjects: 23
Study 11746535 — intervention group
Group type: COMPARATOR
Intervention: Normal-volume leukapheresis (NVL)
Number of subjects: 23
Study 9563288 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial reinforcement in ADHD children
Number of subjects: 22
Study 9563288 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD children
Number of subjects: 22
Study 9563288 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 22
Study 7995977 — intervention group
Group type: EXPERIMENTAL
Intervention: Alovudine at AUC12s of 50, 100, or 200 ng*h/mL for up to 16 weeks
Number of subjects: 60
Study 7995977 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC12 producing a 50% reduction in p24
Number of subjects: 60
Study 3287892 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg/d)
Number of subjects: 37
Study 30825389 — intervention group
Group type: EXPERIMENTAL
Intervention: B12-FAS (delayed arm)
Number of subjects: 161
Study 30825389 — intervention group
Group type: COMPARATOR
Intervention: B12-FAS (immediate arm)
Number of subjects: 161
Study 27189323 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 80 mg/m2 twice daily plus nab-paclitaxel 220 mg/m2 on day 1
Number of subjects: 16
Study 27189323 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 80 mg/m2 twice daily plus nab-paclitaxel 260 mg/m2 on day 1
Number of subjects: 16
Study 27189323 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 and nab-paclitaxel combination therapy
Number of subjects: 16
Study 25683266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 nights of 10 hours sleep extension
Number of subjects: 19
Study 25683266 — intervention group
Group type: COMPARATOR
Intervention: Targeted acoustic stimuli
Number of subjects: 19
Study 23289543 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive disclosure about their disease
Number of subjects: 48
Study 23289543 — intervention group
Group type: COMPARATOR
Intervention: No disclosure (control group)
Number of subjects: 48
Study 23289543 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive disclosure (for those low in Ambivalence over Emotional Expression - AEE)
Number of subjects: 48
Study 23289543 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive disclosure (for those high in AEE)
Number of subjects: 48
Study 23289543 — intervention group
Group type: COMPARATOR
Intervention: Control group (for those high in AEE)
Number of subjects: 48
Study 21320109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg/day
Number of subjects: 547
Study 21320109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 1,200 mg/day
Number of subjects: 547
Study 21320109 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined carisbamate doses
Number of subjects: 547
Study 21320109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 21320109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 1,200 mg
Number of subjects: 547
Study 21320109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg
Number of subjects: 547
Study 19276857 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g L-arginine before resistance exercise
Number of subjects: 18
Study 19276857 — intervention group
Group type: COMPARATOR
Intervention: Placebo before resistance exercise
Number of subjects: 18
Study 17093165 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 178
Study 17093165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 15020659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 80 mg combined with LHRH agonist
Number of subjects: 205
Study 15020659 — intervention group
Group type: COMPARATOR
Intervention: LHRH agonist monotherapy
Number of subjects: 205
Study 11293456 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditions expected to produce positive transfer via dimension differentiation
Number of subjects: 0
Study 11293456 — intervention group
Group type: COMPARATOR
Intervention: Conditions expected to produce positive transfer via selective attention
Number of subjects: 0
Study 11293456 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial and final categorizations sharing relevant or irrelevant dimensions
Number of subjects: 0
Study 11293456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both irrelevant dimensions becoming relevant and relevant dimensions becoming irrelevant
Number of subjects: 0
Study 9176019 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (2 ng min‐1 kg‐1)
Number of subjects: 8
Study 9176019 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (8 ng min‐1 kg‐1)
Number of subjects: 8
Study 9176019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 8
Study 7937815 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) mapping of the hand sensorimotor area
Number of subjects: 0
Study 7937815 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 0
Study 31079973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 1167
Study 31079973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus VKA
Number of subjects: 1167
Study 31079973 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus VKA
Number of subjects: 1167
Study 31079973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel plus VKA
Number of subjects: 1167
Study 31079973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 1167
Study 31079973 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel alone
Number of subjects: 1167
Study 31079973 — intervention group
Group type: EXPERIMENTAL
Intervention: No antithrombotic medication
Number of subjects: 1167
Study 31079973 — intervention group
Group type: COMPARATOR
Intervention: History of AF
Number of subjects: 1167
Study 29232592 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF
Number of subjects: 83
Study 29232592 — intervention group
Group type: COMPARATOR
Intervention: ATO
Number of subjects: 83
Study 29232592 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF and ATO
Number of subjects: 83
Study 26644184 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 393
Study 26644184 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 393
Study 26644184 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 393
Study 24736677 — intervention group
Group type: EXPERIMENTAL
Intervention: B12 Supplement (oral cyanocobalamin 6 μg/day)
Number of subjects: 62
Study 24736677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24736677 — intervention group
Group type: COMPARATOR
Intervention: B12 Dietary Advice
Number of subjects: 62
Study 22093652 — intervention group
Group type: EXPERIMENTAL
Intervention: Taekwondo training (1 hour per day for three months)
Number of subjects: 44
Study 22093652 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 44
Study 20624510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and cognitive behavioral therapy (EX/CBT)
Number of subjects: 74
Study 20624510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 74
Study 20624510 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 74
Study 20624510 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 74
Study 18923204 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation with demand dilatation
Number of subjects: 69
Study 18923204 — intervention group
Group type: COMPARATOR
Intervention: Per-oral endoscopic dilatation alone
Number of subjects: 69
Study 15565164 — intervention group
Group type: EXPERIMENTAL
Intervention: All trans retinoic acid (ATRA) and chemotherapy
Number of subjects: 129
Study 12729868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 33
Study 12729868 — intervention group
Group type: COMPARATOR
Intervention: Control Therapy (intensive occupational therapy activities)
Number of subjects: 33
Study 10323627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 50
Study 10323627 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo (control)
Number of subjects: 50
Study 8704751 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher training program for health personnel in areas A and B
Number of subjects: 1600
Study 8704751 — intervention group
Group type: EXPERIMENTAL
Intervention: Community education program in areas A and C
Number of subjects: 1600
Study 8704751 — intervention group
Group type: COMPARATOR
Intervention: No intervention in area D
Number of subjects: 1600
Study 8704751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention areas A and B
Number of subjects: 1600
Study 1672634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (54 micrograms)
Number of subjects: 30
Study 1672634 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (1.95 mg)
Number of subjects: 30
Study 6216093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g mezlocillin three times
Number of subjects: 96
Study 6216093 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g cefuroxime three times
Number of subjects: 96
Study 31557895 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity (PA)
Number of subjects: 199
Study 31557895 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured physical activity (PA) using accelerometer
Number of subjects: 199
Study 31557895 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's physical activity (PA) measured using accelerometer
Number of subjects: 199
Study 31557895 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's body composition assessed using TANITA bioelectrical impedance device
Number of subjects: 199
Study 31557895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy body mass index (BMI) of mothers
Number of subjects: 199
Study 29480965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal nerve block (ICNB) treatment (Group B)
Number of subjects: 81
Study 29480965 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil treatment (Group A)
Number of subjects: 81
Study 27909127 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic management
Number of subjects: 273
Study 27909127 — intervention group
Group type: COMPARATOR
Intervention: Open management
Number of subjects: 273
Study 25444576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/day soluble milk proteins rich in leucine (PRO)
Number of subjects: 48
Study 25444576 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training
Number of subjects: 48
Study 21718373 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based fissure sealant
Number of subjects: 30
Study 21718373 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite resin
Number of subjects: 30
Study 20194853 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC+IFN‐alpha+Talpha1 (3.2 mg)
Number of subjects: 488
Study 20194853 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC+Talpha1 (3.2 mg)
Number of subjects: 488
Study 20194853 — intervention group
Group type: COMPARATOR
Intervention: Control group (DTIC+IFN‐alpha)
Number of subjects: 488
Study 20194853 — intervention group
Group type: EXPERIMENTAL
Intervention: Talpha1 (any dosage)
Number of subjects: 488
Study 18629317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 200 microg/m(3)
Number of subjects: 27
Study 18629317 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) at 100 microg/m(3)
Number of subjects: 27
Study 18629317 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 27
Study 16171841 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiment 1
Number of subjects: 0
Study 16171841 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiment 2
Number of subjects: 0
Study 16171841 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiment 3
Number of subjects: 0
Study 16171841 — intervention group
Group type: COMPARATOR
Intervention: Lone distracter (anti-target) presented without a target in Experiment 4
Number of subjects: 0
Study 16171841 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distracter (green) presented with a red target in Experiments 5 and 6
Number of subjects: 0
Study 12385067 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of sublingual stabilized NADH (n = 18)
Number of subjects: 35
Study 12385067 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo tablets (n = 17)
Number of subjects: 35
Study 10212076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg, 8 hourly)
Number of subjects: 10
Study 10212076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7754011 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA at doses of 10, 25, 50, and 100 mumol/kg
Number of subjects: 44
Study 7754011 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-EOB-DTPA
Number of subjects: 44
Study 2309538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (10 micrograms.kg‐1 loading dose and 2 micrograms.kg‐1 increments)
Number of subjects: 39
Study 2309538 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (100 micrograms.kg‐1 initial loading dose and either 20 micrograms.kg‐1 increments or 1 microgram.kg‐1.min‐1 continuous infusion)
Number of subjects: 39
Study 2309538 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (100 micrograms.kg‐1 initial loading dose)
Number of subjects: 39
Study 121645 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus glibenclamide
Number of subjects: 10
Study 121645 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus gliclazide
Number of subjects: 10
Study 30796127 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Community Exercise and Education Programme (DCEP)
Number of subjects: 220
Study 30796127 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220
Study 29283913 — intervention group
Group type: EXPERIMENTAL
Intervention: Round Window Approach (RWA)
Number of subjects: 46
Study 29283913 — intervention group
Group type: COMPARATOR
Intervention: Standard Cochleostomy Approach (SCA)
Number of subjects: 46
Study 29283913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RWA and SCA)
Number of subjects: 46
Study 27348907 — intervention group
Group type: EXPERIMENTAL
Intervention: Plum-blossom needle tapping at Jiaji (EX-B 2) combined with rehabilitation
Number of subjects: 60
Study 27348907 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 60
Study 25251930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola crenulata/Cordyceps sinensis supplementation (1400 mg R + 600 mg C per day)
Number of subjects: 18
Study 25251930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25251930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola crenulata/Cordyceps sinensis supplementation (RC)
Number of subjects: 18
Study 25251930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RC and Placebo)
Number of subjects: 18
Study 22483761 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate solution (0.18% SH)
Number of subjects: 304
Study 22483761 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 304
Study 22483761 — intervention group
Group type: COMPARATOR
Intervention: carbomer
Number of subjects: 304
Study 20447652 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose quetiapine (100-400 mg/day)
Number of subjects: 33
Study 20447652 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 33
Study 18929262 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon3 self-ligating brackets
Number of subjects: 62
Study 18929262 — intervention group
Group type: COMPARATOR
Intervention: Synthesis conventionally ligated brackets
Number of subjects: 62
Study 18929262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both appliances
Number of subjects: 62
Study 16083781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg
Number of subjects: 21
Study 16083781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 microg
Number of subjects: 21
Study 16083781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12953283 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustered survival times
Number of subjects: 0
Study 12953283 — intervention group
Group type: COMPARATOR
Intervention: Clustered survival time design
Number of subjects: 0
Study 11096139 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of management interventions for ESRD
Number of subjects: 12000
Study 11096139 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic search methodology
Number of subjects: 12000
Study 11096139 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of a register of randomized controlled trials (RCTs)
Number of subjects: 12000
Study 8783319 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (opiate antagonist)
Number of subjects: 0
Study 8783319 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide (cholecystokinin antagonist)
Number of subjects: 0
Study 8783319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1450090 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan
Number of subjects: 25
Study 1450090 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 25
Study 1450090 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 25
Study 3893508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg orally)
Number of subjects: 15
Study 3893508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31126574 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy milk (240 ml/day for 8 weeks)
Number of subjects: 66
Study 31126574 — intervention group
Group type: COMPARATOR
Intervention: Control group (500-calorie deficit diet without soy milk)
Number of subjects: 66
Study 28361752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 220
Study 28361752 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern diet (high in grains, dairy, and sugar; low in vegetables, fish, and poultry)
Number of subjects: 220
Study 28361752 — intervention group
Group type: COMPARATOR
Intervention: Traditional diet (reciprocal of Modern)
Number of subjects: 220
Study 26712220 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 307
Study 26712220 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Number of subjects: 307
Study 26712220 — intervention group
Group type: EXPERIMENTAL
Intervention: COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin)
Number of subjects: 307
Study 25148829 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day + fenofibrate 200 mg/day
Number of subjects: 42
Study 25148829 — intervention group
Group type: COMPARATOR
Intervention: pravastatin 40 mg/day
Number of subjects: 42
Study 21801104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream (4% lidocaine)
Number of subjects: 40
Study 21801104 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (2.5%)
Number of subjects: 40
Study 21801104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19561035 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration plus exercise three times per week for four weeks
Number of subjects: 16
Study 19561035 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone three times per week for four weeks
Number of subjects: 16
Study 17468312 — intervention group
Group type: EXPERIMENTAL
Intervention: 4DS instructors
Number of subjects: 95
Study 17468312 — intervention group
Group type: COMPARATOR
Intervention: Faculty instructors
Number of subjects: 95
Study 17468312 — intervention group
Group type: EXPERIMENTAL
Intervention: 4DS teaching experience
Number of subjects: 95
Study 16335883 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 40 mg plus HCTZ 12.5 mg (T40/H12.5)
Number of subjects: 805
Study 16335883 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg plus HCTZ 12.5 mg (T80/H12.5)
Number of subjects: 805
Study 12003701 — intervention group
Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0
Study 12003701 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 12003701 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 12003701 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0